Masimo Taps Katie Szyman

Masimo Taps Katie Szyman as Permanent CEO
Masimo appointed Katie Szyman as its next chief executive officer after a proxy fight forced out the company’s founder. Szyman will become CEO of the medical-device maker Feb. 12, replacing interim CEO Michelle Brennan.
Masimo taps Becton Dickinson executive Katie Szyman as CEO (Jan. 21)
(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday,
Masimo picks Katie Szyman as CEO
Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her appointment “fits like a glove,” BTIG analyst Marie Thibault wrote.
Masimo names former Edwards Critical Care leader Katie Szyman as next CEO
Masimo (Nasdaq: MASI) + Masimo Corporation $172.4 1.44% Open 173.198 Day High 175.067 52 Week High 147.89 52 Week Low 75.22 announced today that it appointed Katie Szyman as its new CEO, effective Feb. 12, 2025.
Masimo Appoints Katie Szyman as Permanent CEO
Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide president of BD Advanced Patient Monitoring, the former Critical Care unit of Edwards Lifesciences Corp. that was acquired by Becton, Dickinson and Co. last year for $4.2 billion.
Masimo names Becton Dickinson's Katie Szyman CEO
Masimo said on Tuesday it has named Becton Dickinson executive Katie Szyman as chief executive officer after a bitter proxy battle with activist hedge fund Politan Capital Management led to the ouster of founder Joe Kiani from the medical device maker's board last year.
Needham & Company LLC Reiterates “Hold” Rating for Masimo (NASDAQ:MASI)
Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.
FierceBiotech19h
Masimo lands new CEO from BD's patient monitoring division
After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
Cautious Optimism Amid Leadership Change and Strategic Uncertainty at Masimo
Needham analyst Michael Matson has maintained their neutral stance on MASI stock, giving a Hold rating on January 17.Invest with Confidence: ...
Business Wire2d
Masimo Announces Leadership Transition
Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...
MassDevice7d
Masimo expects healthcare sales to grow around 10% in 2025
Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...
Piper Sandler Sticks to Its Buy Rating for Masimo (MASI)
Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...
Yahoo Finance3d
Masimo Stock Gains Following Solid Preliminary Q4 Revenues
Masimo Corporation MASI announced preliminary revenues for the fourth quarter and full year 2024 on Thursday. Following the robust preliminary results, the company’s shares gained nearly 0.1% ...